CN115536752A - 抗原受体及其用途 - Google Patents

抗原受体及其用途 Download PDF

Info

Publication number
CN115536752A
CN115536752A CN202210717765.1A CN202210717765A CN115536752A CN 115536752 A CN115536752 A CN 115536752A CN 202210717765 A CN202210717765 A CN 202210717765A CN 115536752 A CN115536752 A CN 115536752A
Authority
CN
China
Prior art keywords
antigen
domain
cells
peptide chain
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210717765.1A
Other languages
English (en)
Chinese (zh)
Inventor
拉尔夫·霍尔格·沃斯
乌尔·沙欣
马蒂亚斯·西奥博尔德
彼得拉·西蒙
马蒂亚斯·比特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Biontech Cell and Gene Therapies GmbH
Original Assignee
Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Biontech Cell and Gene Therapies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers, Biontech Cell and Gene Therapies GmbH filed Critical Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Publication of CN115536752A publication Critical patent/CN115536752A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210717765.1A 2015-10-07 2016-10-05 抗原受体及其用途 Pending CN115536752A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2015/073156 WO2017059900A1 (en) 2015-10-07 2015-10-07 Antigen receptors and uses thereof
EPPCT/EP2015/073156 2015-10-07
PCT/EP2016/073792 WO2017060300A1 (en) 2015-10-07 2016-10-05 Antigen receptors and uses thereof
CN201680058729.1A CN108137673B (zh) 2015-10-07 2016-10-05 抗原受体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680058729.1A Division CN108137673B (zh) 2015-10-07 2016-10-05 抗原受体及其用途

Publications (1)

Publication Number Publication Date
CN115536752A true CN115536752A (zh) 2022-12-30

Family

ID=54288785

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210717765.1A Pending CN115536752A (zh) 2015-10-07 2016-10-05 抗原受体及其用途
CN201680058729.1A Active CN108137673B (zh) 2015-10-07 2016-10-05 抗原受体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680058729.1A Active CN108137673B (zh) 2015-10-07 2016-10-05 抗原受体及其用途

Country Status (19)

Country Link
US (4) US20180282390A1 (cg-RX-API-DMAC7.html)
EP (2) EP3359563B8 (cg-RX-API-DMAC7.html)
JP (1) JP6657393B2 (cg-RX-API-DMAC7.html)
KR (1) KR102084173B1 (cg-RX-API-DMAC7.html)
CN (2) CN115536752A (cg-RX-API-DMAC7.html)
AU (1) AU2016335217B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018006006A2 (cg-RX-API-DMAC7.html)
CA (1) CA2998450C (cg-RX-API-DMAC7.html)
DK (1) DK3359563T3 (cg-RX-API-DMAC7.html)
ES (1) ES2748224T3 (cg-RX-API-DMAC7.html)
HU (1) HUE046749T2 (cg-RX-API-DMAC7.html)
IL (1) IL258079B (cg-RX-API-DMAC7.html)
MX (1) MX378368B (cg-RX-API-DMAC7.html)
NZ (1) NZ740474A (cg-RX-API-DMAC7.html)
PL (1) PL3359563T3 (cg-RX-API-DMAC7.html)
PT (1) PT3359563T (cg-RX-API-DMAC7.html)
SI (1) SI3359563T1 (cg-RX-API-DMAC7.html)
WO (2) WO2017059900A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801607B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018166589A1 (en) 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
CN109535257B (zh) 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途
KR20210109520A (ko) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
EP3917969A4 (en) * 2019-01-28 2023-02-01 Wuxi Biologics Ireland Limited NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES
WO2021190580A1 (en) * 2020-03-26 2021-09-30 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific polypeptide complexes, compositions, and methods of preparation and use
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023215725A1 (en) * 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2026148122A1 (en) * 2024-12-31 2026-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Car with dual-variable-domain and enhanced tcr-signaling (cadet) and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE102006041455B4 (de) * 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
EP2388266B1 (en) * 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
BR112013002167A2 (pt) * 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
JP2014511836A (ja) * 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
WO2018166589A1 (en) * 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof

Also Published As

Publication number Publication date
JP6657393B2 (ja) 2020-03-04
AU2016335217A8 (en) 2018-04-12
CA2998450A1 (en) 2017-04-13
HUE046749T2 (hu) 2020-03-30
PL3359563T3 (pl) 2020-03-31
CN108137673B (zh) 2022-07-12
US20230119334A1 (en) 2023-04-20
US20220033461A1 (en) 2022-02-03
ZA201801607B (en) 2020-11-25
DK3359563T3 (da) 2019-09-30
CN108137673A (zh) 2018-06-08
CA2998450C (en) 2020-06-23
HK1259455A1 (en) 2019-11-29
IL258079A (en) 2018-05-31
IL258079B (en) 2021-07-29
US20180282390A1 (en) 2018-10-04
PT3359563T (pt) 2019-10-18
RU2018112327A3 (cg-RX-API-DMAC7.html) 2019-11-12
JP2018530331A (ja) 2018-10-18
KR20180057648A (ko) 2018-05-30
KR102084173B1 (ko) 2020-03-03
MX2018004121A (es) 2018-05-17
ES2748224T3 (es) 2020-03-16
RU2018112327A (ru) 2019-11-07
WO2017059900A1 (en) 2017-04-13
EP3359563B1 (en) 2019-07-31
EP3359563B8 (en) 2019-10-02
WO2017060300A1 (en) 2017-04-13
HK1255312A1 (zh) 2019-08-16
AU2016335217B2 (en) 2021-04-29
MX378368B (es) 2025-03-10
EP3359563A1 (en) 2018-08-15
SI3359563T1 (sl) 2019-11-29
NZ740474A (en) 2022-09-30
US20260091060A1 (en) 2026-04-02
AU2016335217A1 (en) 2018-03-29
BR112018006006A2 (en) 2018-10-30
EP3617226A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
US20260091060A1 (en) Antigen receptors and uses thereof
JP6914851B2 (ja) 核酸ワクチン接種によるｃａｒ操作ｔ細胞の効果の増強
KR102396925B1 (ko) 항원 수용체 및 이의 용도
RU2792042C2 (ru) Антигенные рецепторы и их применения
RU2794945C2 (ru) Антигенные рецепторы и их применение
HK40018015A (en) Antigen receptors and uses thereof
HK1259455B (en) Antigen receptors and uses thereof
HK1255312B (en) Antigen receptors and uses thereof
HK40021775A (en) Antigen receptors and uses thereof
HK40021775B (en) Antigen receptors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination